pembrolizumab mesothelioma

KEYNOTE-483 added pembrolizumab to chemo, extending pleural mesothelioma median survival to 17.3 months. What the Sept 2024 FDA approval means in 2026.

Mesothelin-targeted CAR-T therapy reached a 72% response rate when combined with pembrolizumab at MSKCC. Learn how engineered T cells are changing mesothelioma treatment in 2026.

ASCO's 2025 guideline update makes dual immunotherapy the standard first-line treatment for mesothelioma. Review survival data, eligibility, and next steps.

Real-world data reveals older mesothelioma patients on immunotherapy survive 25% less than clinical trial participants. Learn what the gap means for treatment decisions.

The 2025 ASCO guideline now recognizes 3 first-line mesothelioma regimens. Compare surgery, chemotherapy, and immunotherapy outcomes using CheckMate 743 five-year data and 2024 FDA approvals.